SweetBio
SweetBio is a Memphis-based medical device company that develops and sells FDA-cleared, Medicare-covered bioengineered wound care dressings (APIS and VERIS) combining Mānuka honey, collagen, and hydroxyapatite for chronic and acute wound treatment in clinical, dermatology, and VA/DOD settings.
- Company typePrivate
- Founded2015
- HeadquartersMemphis, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What SweetBio does
SweetBio is a privately-held medical device company founded in 2015 and headquartered at the University of Memphis CommuniTech Research Park. The company develops and commercializes bioengineered wound care products built on a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite — protected by granted patent and supported by 15 years of foundational tissue engineering research by co-founder and CSO Dr. Isaac Rodriguez. SweetBio sells two FDA-cleared, Medicare-covered products: VERIS, a daily collagen dressing reimbursed under HCPCS A6021 for routine clinic wounds, and APIS, a weekly cellular and/or tissue-based product (CTP/skin substitute) reimbursed under HCPCS A2010 for chronic and acute wounds. Clinical evidence includes a 37-patient Mohs RCT at Vanderbilt, a 12-patient chronic wound case series showing 100% closure within 8 weeks, and a 43-patient urban hospital study demonstrating 2x faster closure versus standard of care.
The company operates a hybrid sales-and-distribution model, selling directly to healthcare providers — including wound care clinics, dermatology departments, and integrated health systems — while leveraging national distribution partners BioLab Holdings and Resolve Medical for channel scale. APIS is now available across all Medicare Administrative Contractors (MACs) and in Veterans Affairs and Department of Defense facilities. SweetBio has raised approximately $4.55 million across multiple rounds led primarily by Innova Memphis with participation from MB Venture Partners, The JumpFund, ZeroTo510, and VamosVentures, plus a 2021 grant from Apple's Racial Equity and Justice Initiative. The company has a 1–10 person team and is led by co-founder and CEO Kayla Rodriguez Graff alongside co-founder and CSO Isaac Rodriguez, PhD, and co-founder/CFO Kevin Graff.
Revenue model is unit-based hardware sales of wound care dressings reimbursed by Medicare and commercial payers. Forward growth depends on conversion of the two newly signed national distribution partnerships and continued clinical adoption across wound care, dermatology, and government health system channels.
SweetBio firmographics
Firmographics- Name
- SweetBio
- Legal name
- SweetBio Inc.
- Website
- https://sweetbio.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SweetBio is a Memphis-based medical device company that develops and sells FDA-cleared, Medicare-covered bioengineered wound care dressings (APIS and VERIS) combining Mānuka honey, collagen, and hydroxyapatite for chronic and acute wound treatment in clinical, dermatology, and VA/DOD settings.
- Ownership category
- akta.pro rank
SweetBio industry classification
Industry- Product category
- Wound Care Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industries
- Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Wound Care & Ulcer Management (HLAKACAN), Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation) (HLAHALAC)
Keywords
Where SweetBio is headquartered
LocationHeadquarters
- HQ city
- Memphis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
SweetBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: Sale of APIS and VERIS wound care products to healthcare providers, clinics, and hospital systems. Revenue generated through product sales with Medicare and commercial insurance reimbursement.
- Distribution Partnership Revenue: Revenue through distribution partners BioLab Holdings and Resolve Medical who distribute SweetBio products through their national networks to healthcare providers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | VERIS - Daily wound dressings |
| Unit Pricing | Pay-as-you-go | APIS - Weekly CTP/skin substitute |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
SweetBio product offering
Product offeringCore offering
SweetBio develops and sells FDA-cleared, Medicare-covered bioengineered wound care dressings built on a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. The company sells two SKUs — VERIS, a daily collagen dressing reimbursed under HCPCS A6021, and APIS, a weekly cellular tissue product/skin substitute reimbursed under HCPCS A2010 — to wound care clinics, dermatology departments, and hospital systems through national distribution partners.
Product overview
SweetBio® develops bioengineered wound care products using a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. The company offers two products: VERIS™ (daily collagen dressings for routine wound care, HCPCS A6021) and APIS® (weekly skin substitute/CTP for chronic and acute wounds, HCPCS A2010). Both products are FDA-cleared, Medicare-covered, and clinically proven to reduce time to wound closure compared to standard of care.
Differentiator
Problem solved
Functional benefit
Brands
- APIS®: Weekly CTP / skin substitute supporting both chronic and acute wounds. The first wound care product combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. FDA-cleared and Medicare-covered.
- VERIS™
Products and services
- VERIS™ VERIS is a daily wound dressing combining collagen and Mānuka honey for routine use in clinic settings. It is FDA-cleared, reimbursed by Medicare and most commercial plans as a low-cost wound supply (HCPCS A6021, collagen), and designed for healthcare providers treating common wounds seen every day in clinic.
- APIS® APIS is a weekly cellular tissue product (CTP) / skin substitute combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite for the treatment of chronic and acute wounds. It is FDA-cleared, non-human (no placental, umbilical, or other human tissue), Medicare-covered under HCPCS A2010, and available across MACs and in Veterans Affairs and Department of Defense facilities.
Quantifiable outcome
- 100% wound closure within 8 weeks (mean 4.1 weeks) in 12-patient chronic wound case series
- +4 more outcomes
Companies that use SweetBio
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
SweetBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
SweetBio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- BioLab HoldingscoreStrategic distribution partnership to expand access to SweetBio's APIS bioengineered wound care products through BioLab's national distribution network. Expected to accelerate adoption among clinicians across care settings while strengthening BioLab's continuum-of-care portfolio.
- Resolve MedicalcoreCommercial launch partnership for APIS through Resolve Medical's established network of healthcare providers across the United States. Resolve Medical leads product distribution and launch activities.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
SweetBio competitors and assessment
Company assessmentEmerging players
- Resolve Medical: Specialty distributor focused on bringing advanced wound care products to US healthcare providers; leads APIS® commercial launch. Comparable as a channel peer and emerging commercialization partner in the advanced wound care category.
- BioLab Holdings: Wound care distributor that recently added SweetBio's APIS® to its national portfolio. Comparable as a strategic channel peer whose continuum-of-care portfolio increasingly competes with and complements bioengineered skin substitute offerings.
Broad incumbents
- ConvaTec Group: Major advanced wound care incumbent offering foam, hydrocolloid, antimicrobial, and biologic wound dressings. Overlaps with SweetBio on collagen and antimicrobial wound dressings (similar HCPCS A-codes) but operates at significantly broader global scale.
- Medline Industries: Largest privately-held manufacturer and distributor of medical supplies, including a broad wound care portfolio. Comparable as both a competing supplier and a channel partner option for SweetBio's hospital and clinic customers.
- 3M Health Care (KCI): Owns the KCI negative pressure wound therapy franchise plus a range of advanced wound dressings. Comparable as a large channel competitor in advanced wound care, especially for hospital systems where SweetBio sells through BioLab and Resolve Medical.
- Smith & Nephew: Global medical device incumbent with a large Advanced Wound Management portfolio (collagen dressings, honey-based dressings, skin substitutes via the Osiris acquisition). Comparable in product overlap (collagen/honey wound dressings, CTP/skin substitutes) though operating at much greater scale across multiple categories.
- Coloplast: Global wound and skin care company with extensive advanced wound dressings portfolio. Overlaps with SweetBio on collagen-based and antimicrobial wound dressings sold into similar healthcare provider and outpatient settings.
- Integra LifeSciences: Diversified regenerative medicine company with skin substitutes (e.g., Integra Dermal Regeneration Template) and wound care products. Comparable on regenerative skin substitute technology and Medicare-reimbursed wound care sales channels.
Direct peers
- MiMedx Group: Develops and markets placental tissue allografts used as skin substitutes and wound coverings. Directly comparable to SweetBio in product category (skin substitute/CCTPs), reimbursement dynamics under HCPCS Q-codes/A-codes, and target customer (wound care clinics, dermatologists, VA/DOD).
- Organogenesis Holdings: A leading regenerative medicine company commercializing skin substitutes and wound care biologics (e.g., Apligraf, Dermagraft). Directly comparable to SweetBio as both sell FDA-cleared, Medicare-covered skin substitutes/CTPs into the chronic and acute wound care market under similar HCPCS reimbursement pathways.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
SweetBio social profiles
Digital presenceSweetBio compliance and trust
Trust signalCompliance1 record
SweetBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
SweetBio leadership team
Management profileNumber of profiles
Profiles3 records
SweetBio funding detail
Funding detailFunding overview
Funding rounds7 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SweetBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SweetBio
What does SweetBio do?
SweetBio develops and sells FDA-cleared, Medicare-covered bioengineered wound care dressings built on a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. The company sells two SKUs — VERIS, a daily collagen dressing reimbursed under HCPCS A6021, and APIS, a weekly cellular tissue product/skin substitute reimbursed under HCPCS A2010 — to wound care clinics, dermatology departments, and hospital systems through national distribution partners.
Is SweetBio a public or private company?
SweetBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was SweetBio founded?
SweetBio was founded in 2015. It employs 1 to 10 people.
Where is SweetBio based?
SweetBio is headquartered in Memphis, United States, in the North America region.
How does SweetBio make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are distribution Partnership Revenue.
Who are SweetBio's main competitors?
Emerging players on record are Resolve Medical and BioLab Holdings. Broad incumbents are ConvaTec Group, Medline Industries, 3M Health Care (KCI), Smith & Nephew, Coloplast and Integra LifeSciences. Direct peers are MiMedx Group and Organogenesis Holdings.
Does SweetBio have an API?
No public API is recorded for SweetBio.
What industry is SweetBio in?
SweetBio's product category is Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 3391 and its SIC code is 3841.